Make money doing the work you believe in
$ALT ORAL PEMV (MASH)
In 2024 Dr. Harris spoke about an Oral Formulation for MASH
Oral talks disappeared, but did the option disappear?
No. It did not.
ALT said in filings:
The Company, via its wholly-owned subsidiary Spitfire Pharma, LLC, entered into a Collaboration and License Agreement with Adocia S.A. on December 24, 2024 under which the Company has exclusive rights to intellectual property pertaining to oral administration of pemvidutide, with patent applications pending, which if issued, would have an expiration date of no later than June 2043, and a US patent issuing in February 2026 that will have an expiration date no later than December 2044.
Adocia said on APRIL 21 2026!!!
The feasibility study conducted with an undisclosed partner for an application to a new incretin with AdOral® has NOW been COMPLETED. The platform potential of AdOral® has been confirmed by this study, and the decision regarding the next steps for the programme will depend on the partner’s strategy